Acute Lymphoblastic Leukemia
The evolving treatment landscape in ALL: the growing role of immunotherapy and reduced reliance on chemotherapy
There has been a significant shift in the treatment of acute lymphoblastic leukemia (ALL), driven by the emergence of novel…
Date: 14th August 2026
The diagnosis and management of hematologic malignancies during pregnancy
In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares…
Date: 16th July 2026
MRD in ALL and AML: from prognostic marker to clinical endpoint
This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic…
Date: 20th March 2026
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly…
Date: 27th February 2025
A focus on pediatric leukemias: trials, treatments, & challenges
Welcome to the third episode of VJHemOnc’s Blood Cancer Awareness Month special series! The focus of this episode is pediatric…
Date: 25th September 2024
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
Welcome to the first episode of VJHemOnc’s Blood Cancer Awareness Month special series! This episode focuses on global perspectives of…
Date: 9th September 2024
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells…
Date: 22nd February 2024
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 18th May 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…
Date: 10th March 2023
iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 22nd November 2022
iwAL 2022 Session II: novel treatment strategies in ALL
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 4th November 2022
The future of CAR-T therapy in ALL
Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been…
Date: 20th July 2022
